
JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (8): 1009-1016.doi: 10.3969/j.issn.1674-8115.2021.08.003
• Basic research • Previous Articles Next Articles
Bing-qian ZHOU(
), Li HAN, Zhe-yi CHEN, Shi-yu CHEN, Ying-xia ZHENG(
)
Online:2021-08-28
Published:2021-08-13
Contact:
Ying-xia ZHENG
E-mail:bettyerzhou@163.com;combi3230@163.com
Supported by:CLC Number:
Bing-qian ZHOU, Li HAN, Zhe-yi CHEN, Shi-yu CHEN, Ying-xia ZHENG. Expression of protein arginine methyltransferase 5 in lung cancer and its mechanism of promoting lung cancer[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021,(8): 1009-1016.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2021.08.003
| Intensity of PRMT5 expression | Proportion of PRMT5-positive cells | Score |
|---|---|---|
| Negative | 0 | 0 |
| Weakly positive | 0‒25% | 1 |
| Moderately positive | 25%‒50% | 2 |
| Strongly positive | 50%‒75% | 3 |
| No stronger intensity | 75%‒100% | 4 |
Tab 1 PRMT5 expression scoring criteria
| Intensity of PRMT5 expression | Proportion of PRMT5-positive cells | Score |
|---|---|---|
| Negative | 0 | 0 |
| Weakly positive | 0‒25% | 1 |
| Moderately positive | 25%‒50% | 2 |
| Strongly positive | 50%‒75% | 3 |
| No stronger intensity | 75%‒100% | 4 |
| shRNA | Sequence (5′→3′) |
|---|---|
| NC-shRNA | F: GATCTGTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTTC |
| R: AATTCAAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGTGACACGTTCGGAGAACA | |
| PRMT5-shRNA1 | F: GATCCGCCCAGTTTGAGATGCCTTATTTCAAGAGAATAAGGCATCTCAAACTGGGCTTTTTTG |
| R: AATTCAAAAAAGCCCAGTTTGAGATGCCTTATTCTCTTGAAATAAGGCATCTCAAACTGGGCG | |
| PRMT5-shRNA2 | F: GATCCGGCTGACCTCCCATCTAATCATTCAAGAGATGATTAGATGGGAGGTCAGCCTTTTTTG |
| R: AATTCAAAAAAGGCTGACCTCCCATCTAATCATCTCTTGAATGATTAGATGGGAGGTCAGCCG | |
| PRMT5-shRNA3 | F: GATCCCCCATCCTCTTCCCTATTAAGCTTCCTGTCAGACTTAATAGGGAAGAGGATGGGTTTTTG |
| R: AATTCAAAAACCCATCCTCTTCCCTATTAAGTCTGACAGGAAGCTTAATAGGGAAGAGGATGGGG |
Tab 2 Oligonucleotide sequence of shRNA
| shRNA | Sequence (5′→3′) |
|---|---|
| NC-shRNA | F: GATCTGTTCTCCGAACGTGTCACGTTTCAAGAGAACGTGACACGTTCGGAGAATTTTTTC |
| R: AATTCAAAAAATTCTCCGAACGTGTCACGTTCTCTTGAAACGTGACACGTTCGGAGAACA | |
| PRMT5-shRNA1 | F: GATCCGCCCAGTTTGAGATGCCTTATTTCAAGAGAATAAGGCATCTCAAACTGGGCTTTTTTG |
| R: AATTCAAAAAAGCCCAGTTTGAGATGCCTTATTCTCTTGAAATAAGGCATCTCAAACTGGGCG | |
| PRMT5-shRNA2 | F: GATCCGGCTGACCTCCCATCTAATCATTCAAGAGATGATTAGATGGGAGGTCAGCCTTTTTTG |
| R: AATTCAAAAAAGGCTGACCTCCCATCTAATCATCTCTTGAATGATTAGATGGGAGGTCAGCCG | |
| PRMT5-shRNA3 | F: GATCCCCCATCCTCTTCCCTATTAAGCTTCCTGTCAGACTTAATAGGGAAGAGGATGGGTTTTTG |
| R: AATTCAAAAACCCATCCTCTTCCCTATTAAGTCTGACAGGAAGCTTAATAGGGAAGAGGATGGGG |
| Primer | Forward (5’→3’) | Reverse (5’→3’) |
|---|---|---|
| PRMT5 | CGATCAGACCTACTGCTGTCA | CTCGGAGTTCCTGCGAATCT |
| β-actin | CATGTACGTTGCTATCCAGGC | CTCCTTAATGTCACGCACGAT |
| VIM | GACGCCATCAACACCGAGTT | CTTTGTCGTTGGTTAGCTGGT |
| SNAI1 | TCGGAAGCCTAACTACAGCGA | AGATGAGCATTGGCAGCGAG |
| CDH1 | ATTTTTCCCTCGACACCCGAT | TCCCAGGCGTAGACCAAGA |
Tab 3 Primer sequences for qPCR
| Primer | Forward (5’→3’) | Reverse (5’→3’) |
|---|---|---|
| PRMT5 | CGATCAGACCTACTGCTGTCA | CTCGGAGTTCCTGCGAATCT |
| β-actin | CATGTACGTTGCTATCCAGGC | CTCCTTAATGTCACGCACGAT |
| VIM | GACGCCATCAACACCGAGTT | CTTTGTCGTTGGTTAGCTGGT |
| SNAI1 | TCGGAAGCCTAACTACAGCGA | AGATGAGCATTGGCAGCGAG |
| CDH1 | ATTTTTCCCTCGACACCCGAT | TCCCAGGCGTAGACCAAGA |
| Clinical feature | Relative expression of PRMT5/score | t value | P value |
|---|---|---|---|
| Gender | 0.191 | 0.849 | |
| Male (n=39) | 6.21±3.00 | ||
| Female (n=34) | 6.08±2.84 | ||
| Age | 0.490 | 0.626 | |
| ≥60 year (n=36) | 5.93±2.84 | ||
| <60 year (n=37) | 6.32±2.99 | ||
| TNM stage | 2.178 | 0.033 | |
| Ⅰ‒Ⅱ (n=51) | 5.65±2.75 | ||
| Ⅲ‒Ⅳ (n=22) | 7.24±3.01 | ||
| Pathological grading | 0.370 | 0.712 | |
| T1‒T2 (n=61) | 6.21±3.01 | ||
| T3‒T4 (n=12) | 5.86±2.45 | ||
| Lymph node metastasis metastasis | 0.884 | 0.379 | |
| Yes (n=35) | 5.83±2.54 | ||
| No (n=38) | 6.43±3.21 |
Tab 4 Relationship between the expression of PRMT5 and the clinical features of lung cancer patients
| Clinical feature | Relative expression of PRMT5/score | t value | P value |
|---|---|---|---|
| Gender | 0.191 | 0.849 | |
| Male (n=39) | 6.21±3.00 | ||
| Female (n=34) | 6.08±2.84 | ||
| Age | 0.490 | 0.626 | |
| ≥60 year (n=36) | 5.93±2.84 | ||
| <60 year (n=37) | 6.32±2.99 | ||
| TNM stage | 2.178 | 0.033 | |
| Ⅰ‒Ⅱ (n=51) | 5.65±2.75 | ||
| Ⅲ‒Ⅳ (n=22) | 7.24±3.01 | ||
| Pathological grading | 0.370 | 0.712 | |
| T1‒T2 (n=61) | 6.21±3.01 | ||
| T3‒T4 (n=12) | 5.86±2.45 | ||
| Lymph node metastasis metastasis | 0.884 | 0.379 | |
| Yes (n=35) | 5.83±2.54 | ||
| No (n=38) | 6.43±3.21 |
| 1 | Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. |
| 2 | Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun, 2019, 39(1): 22. |
| 3 | Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis[J]. Cancer Treat Res, 2016, 170: 47-75. |
| 4 | Mehlen P, Puisieux A. Metastasis: a question of life or death[J]. Nat Rev Cancer, 2006, 6(6): 449-458. |
| 5 | Stopa N, Krebs JE, Shechter D. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond[J]. Cell Mol Life Sci, 2015, 72(11): 2041-2059. |
| 6 | Pal S, Baiocchi RA, Byrd JC, et al. Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma[J]. EMBO J, 2007, 26(15): 3558-3569. |
| 7 | Migliori V, Müller J, Phalke S, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance[J]. Nat Struct Mol Biol, 2012, 19(2): 136-144. |
| 8 | Jing PY, Zhao N, Ye MX, et al. Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling[J]. Cancer Lett, 2018, 427: 38-48. |
| 9 | Chen H, Lorton B, Gupta V, et al. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression[J]. Oncogene, 2017, 36(3): 373-386. |
| 10 | Jiang H, Zhu Y, Zhou ZY, et al. PRMT5 promotes cell proliferation by inhibiting BTG2 expression via the ERK signaling pathway in hepatocellular carcinoma[J]. Cancer Med, 2018, 7(3): 869-882. |
| 11 | Chiang K, Zielinska AE, Shaaban AM, et al. PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression[J]. Cell Rep, 2017, 21(12): 3498-3513. |
| 12 | Nicholas C, Yang J, Peters SB, et al. PRMT5 is upregulated in malignant and metastatic melanoma and regulates expression of MITF and p27(Kip1.)[J]. PLoS One, 2013, 8(9): e74710. |
| 13 | Brabletz T, Kalluri R, Nieto MA, et al. EMT in cancer[J]. Nat Rev Cancer, 2018, 18(2): 128-134. |
| 14 | Ge L, Wang H, Xu X, et al. PRMT5 promotes epithelial-mesenchymal transition via EGFR-β-catenin axis in pancreatic cancer cells[J]. J Cell Mol Med, 2020, 24(2): 1969-1979. |
| 15 | Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. |
| 16 | Shailesh H, Zakaria ZZ, Baiocchi R, et al. Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer[J]. Oncotarget, 2018, 9(94): 36705-36718. |
| 17 | Yuan YY, Nie H. Protein arginine methyltransferase 5: a potential cancer therapeutic target[J]. Cell Oncol (Dordr), 2021, 44(1): 33-44. |
| [1] | Ye Zhiyun, Zhou Yining, Chen Huiwen, He Zhiyan, Zhou Wei, Song Zhongchen. Effects of extracellular vesicles derived from Lactobacillus rhamnosus GG on the biological properties of MC3T3-E1 cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026, 46(9): 1188-1198. |
| [2] | Peng Qianqian, Song Jinghan, Xu Xingyi, Xiao Hui. Bioinformatic analysis and validation of the RNA-binding protein HuR promoting non-small cell lung cancer progression via ITGB1 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026, 46(4): 451-466. |
| [3] | Yin Wenyu, Wang Ruijie, Ma Hailong, Jin Shufang. Study on how histone lysine lactylation regulates zinc finger protein 668 to facilitate proliferation of head and neck squamous cell carcinoma cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026, 46(2): 151-162. |
| [4] | Chen Xinhong, Zhang Xue, Liu Ting, Zhang Shumin, Ma Yupeng, Lai Jiahui, Zhang Zihan, Chi Yongbin. Fatostatin targets SCAP/SREBP pathway to inhibit ARID1A-deficient non-small cell lung cancer by promoting ferroptosis [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026, 46(10): 1355-1365. |
| [5] | ZHU Zijun, QIAN Yife, LI Qianyu, LI Songling, QIN Wenli, LIU Yanfeng. Anaphase-promoting complex subunit 10 promotes hepatocellular carcinoma progression through regulation of the PI3K-AKT-mTOR signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(9): 1171-1182. |
| [6] | HUANG Xin, LIU Jiahui, YE Jingwen, QIAN Wenli, XU Wanxing, WANG Lin. Development and clinical application of a machine learning-driven model for metabolite-based diagnosis of small cell lung cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(8): 1009-1016. |
| [7] | ZHANG Yuqin, AIHEMAITI Yilixiati, WANG Yanli, YANG Zhi, HUANG Jian. Ubiquitination and degradation of RPTPα mediated by MARCH9 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(8): 957-968. |
| [8] | YANG Na, LIU Junli, BAI Jing, YANG Siyi, HAN Jiming, ZHANG Huahua. HENMT1 promotes the proliferation and migration of gastric cancer by activating the PI3K-AKT-mTOR signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(6): 717-726. |
| [9] | XU Muxin, LIU Xian, JIANG Lishan, SUN Qing. Promotion of Nd:YAP laser biostimulation on the proliferation and osteogenic differentiation of human periodontal ligament cells through WNT/β-catenin signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(5): 562-569. |
| [10] | CHEN Yinan, ZHENG Yang, ZENG Hanlin, LEI Ming. Mechanism of Fas-associated protein with death domain in promoting proliferation of head and neck squamous cell carcinoma cells [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(4): 404-414. |
| [11] | ZOU Peichen, LIU Hongyu, AIHEMAITI· Ayinazhaer, ZHU Liang, TANG Yabin, LEI Huimin. Metabolic profiling of lung cancer cells with acquired resistance to sotorasib [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(2): 138-149. |
| [12] | ZHANG Shuqiong, KE Xing, ZHAO Xinghe, CHEN Xiaocui, ZHENG Haodong, CHEN Hui, SHEN Lisong, YANG Junyao. LINC01123 promotes proliferation and glycolysis of gastric cancer via binding to ENO1 [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(11): 1443-1457. |
| [13] | ZHANG Xianzhou, DU Fenglin, WU Lei, REN Yizhe, ZHAO Mingna, LOU Jiatao. Mechanistic study of OGT-promoted non-small cell lung cancer proliferation via the ERK signaling pathway [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(10): 1288-1297. |
| [14] | LI Xiang, WEI Ming, WU Wenxi, LUO Xiaoqin, YAO Biao, WU Siyu. Inhibitory effect of rutin on the growth and metastasis of osteosarcoma in vitro and in vivo [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(1): 20-28. |
| [15] | SUN Chenwei, HAI Wangxi, QU Qian, XI Yun. [18F]F-FMISO and [18F]F-FLT PET/CT dual-nuclide imaging for in vivo prediction of drug resistance in pancreatic cancer [J]. Journal of Shanghai Jiao Tong University (Medical Science), 2025, 45(1): 60-68. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||